Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.8400 (0.64%) ($7.6400 - $7.9700) on Thu. May. 2, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.94% (three month average) | RSI | 43 | Latest Price | $7.8400(0.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.9% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -2.47% in a week (0% probabilities). VXX(-16%) UUP(-11%) TLT(-9%) VIXM(-7%) IFRA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.47% (StdDev 4.94%) | Hourly BBV | 0 () | Intraday Trend | 0.5% | | | |
|
1 - 5 Day Possible Target | $3.1(-60.46%) | Resistance Level | $8.07 | 5 Day Moving Average | $7.9(-0.76%) | 10 Day Moving Average | $7.95(-1.38%) | 20 Day Moving Average | $8.07(-2.85%) | To recent high | -7.5% | To recent low | 51.1% | Market Cap | $993m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |